Search company, investor...


Founded Year



Other Investors | Alive

About Unibioscreen

Unibioscreen is a specialist oncology discovery & development company, with focus on 'first in class' drugs, mainly of natural origin. Unibioscreen has successfully developed 2 drug candidates from discovery to clinical development in cancer patients and has other promising pre-clinical compounds in its pipeline.

Headquarters Location

Avenue Joseph Wybran 40



Missing: Unibioscreen's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Unibioscreen's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Unibioscreen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Unibioscreen is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Unibioscreen Patents

Unibioscreen has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Asclepiadoideae, Indoles, Poisonous plants, Butterfly food plants, Fluoroarenes


Application Date


Grant Date



Related Topics

Asclepiadoideae, Indoles, Poisonous plants, Butterfly food plants, Fluoroarenes



Unibioscreen Frequently Asked Questions (FAQ)

  • When was Unibioscreen founded?

    Unibioscreen was founded in 1999.

  • What is Unibioscreen's latest funding round?

    Unibioscreen's latest funding round is Other Investors.

  • Who are the investors of Unibioscreen?

    Investors of Unibioscreen include ING, SG Asset Management, Brustart, Hunza Ventures, E-Capital and 5 more.

  • Who are Unibioscreen's competitors?

    Competitors of Unibioscreen include Humanetics, Evotec SE, Kiadis Pharma, Activate Immunotherapy, CymaBay Therapeutics, SpiroGen, Clovis Oncology, Novexel, Palkion, BiPar Sciences and 14 more.

Compare Unibioscreen to Competitors


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Functional Genetics

FGI, based in Rockville, Maryland, is developing drugs and diagnostics based on its genome-wide discovery and validation of genes and their roles in human disease. FGI has validated drug candidates for the treatment of infectious disease, drug resistant cancer and Alzheimer's disease.

Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

Stemina Biomarker Discovery Logo
Stemina Biomarker Discovery

Stemina Cell Discovery discovers and validates small molecules as biomarkers for high-throughput drug screening and disease diagnostics using an all human system comprised of stem cells and the company's metabolomics platform. Metabolomics aims to enable the discovery of small molecules that can be used as candidate biomarkers of disease and pharmacological efficacy or toxicity. The human embryonic stem cell metabolome is a source of candidate biomarkers to predict, diagnose or measure the progress of disease or toxic response. Stemina aims to provide compound screening and diagnostic development for the pharmaceutical and biotechnology industries and academia under contract services or joint discovery agreements.

Endotis Pharma

Endotis Pharma is A specialty discovery and development company developing small glycol drugs for thrombosis and oncology

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.